RxDoctor Payments DataLook up a doctor →

Robert Westcott, MD

Family Medicine · Lindsay, OKNPI 1053371435

Payments from drug & device makers

$1,624,019in general payments, 2019–2025

Across 208 payments — averaging $7807.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$1.2M
  • Merck$223K
  • E.r. Squibb & Sons, L.L.C.$176K
  • Galderma Laboratories, L.p.$12K
  • Janssen Research & Development, LLC$4K
  • Novo Nordisk$183
  • plus $313 from 7 others
$261,964in research payments, 2019–2025

Across 9 payments — averaging $29,107 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Orexo US, Inc.$262K

What the payments were for

  • Travel & lodging$86152%
  • Food & beverage$78248%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,624,019 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$46,136
Medicare patients
85
Services billed
764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl310$53,461
OzempicSemaglutide23$35,976
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$25,224
EliquisApixaban24$23,764
JanumetSitagliptin Phos/Metformin Hcl13$20,794
ZubsolvBuprenorphine Hcl/Naloxone Hcl13$15,279
XareltoRivaroxaban12$13,704
MounjaroTirzepatide13$12,383
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$10,569
VascepaIcosapent Ethyl12$7,097
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$6,365
OxycontinOxycodone Hcl13$3,745
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen59$3,096
Insulin Lispro Protamine MixInsulin Lispro Protamin/Lispro12$2,621
Gabapentin80$1,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$183$35,97623 claims
MerckJanumet$222,849$20,79413 claims
Orexo US, Inc.Zubsolv$11$15,27913 claims
Johnson & JohnsonXarelto$111$13,70412 claims
Lilly USA, LLCMounjaro$43$12,38313 claims
Indivior Inc.Suboxone$1,208,472$10,56913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Lindsay

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →